Welcome to our dedicated page for BNB Plus news (Ticker: BNBX), a resource for investors and traders seeking the latest updates and insights on BNB Plus stock.
BNB Plus Corp. (BNBX) generates news across both digital asset and biotechnology domains. As a Nasdaq-listed company that combines a BNB-focused digital asset treasury with nucleic acid production activities, its announcements cover developments in its BNB strategy as well as operational milestones for its LineaDNA platform.
On the digital asset side, BNB Plus issues updates on its BNB treasury holdings, private placements that support its yield-focused strategy, and tools such as the BNBX.io dashboard, which it describes as providing real-time portfolio and company metrics. These disclosures outline how the company is implementing what it calls a transparent, actively managed BNB treasury that blends DeFi and Binance-native yield opportunities.
In biotechnology and diagnostics, the company reports on LineaDNA production and customer activity through its LineaRx subsidiary. Recent news items include record LineaDNA shipments, multi-gram deliveries under supply agreements, and accelerated multi-year orders from customers in the in vitro diagnostics and biotherapeutic markets. These updates highlight the role of LineaDNA as a cell-free DNA platform used in applications such as cancer diagnostic tests.
Corporate and governance developments also feature in BNB Plus news, including its rebranding from Applied DNA Sciences, changes in board leadership, and shareholder approvals related to capital structure and warrant exercisability. Investors and observers can use this news stream to follow how the company advances its dual mandate in BNB-based treasury management and nucleic acid production.
For those tracking BNB Plus, the news page provides a centralized view of treasury updates, financing transactions, LineaDNA orders and shipments, and key corporate actions that the company discloses through press releases.
BNB Plus Corp (NASDAQ: BNBX) will present at the Digital Asset Virtual Investor Conference on January 27, 2026 at 1:00 PM EST. Chief Investment Officer Patrick Horsman, CFA, and Chairman Joshua Kruger will deliver a live presentation and be available for 1x1 meetings Jan 27–29, 2026. The event is an interactive online webcast with live Q&A and an archived replay available afterwards. Attendees are recommended to pre-register and run the system check to ensure participation. Registration and 1x1 scheduling are available via VirtualInvestorConferences.com.
BNB Plus (NASDAQ: BNBX) received a $1.2M accelerated order for LineaDNA, the largest LineaDNA order in company history.
The order accelerates an existing customer's two-year purchasing cadence into a delivery schedule expected to be completed by May 2026, and follows a prior $600,000 follow-on order from July 2025. Inclusive of the new order, the company expects to ship over $1.5M of LineaDNA to IVD and biotherapeutic customers in 1H CY2026. The announcement builds on recent fulfillment, including a LineaDNA shipment valued at over $390,000.
BNB Plus (Nasdaq: BNBX) reported successful production and shipment of the largest single LineaDNA order in company history: an approximately 5-gram delivery valued at over $390,000. The shipment was produced by subsidiary LineaRx and delivered under the company's existing bulk Supply Agreement for LineaDNA used in a cancer diagnostic test.
BNBX said it expects to fulfill additional multi-gram deliveries in the first half of calendar 2026. Management noted ongoing organizational "right sizing" while highlighting operational execution and platform resilience.
BNB Plus (Nasdaq: BNBX) announced corporate updates including a strategic addition to its BNB treasury, operational progress at its LineaRx subsidiary, and a rebrand with a new website at BNB.plus.
The company deployed approximately $3.0 million to acquire ~3,349 BNB at an average price of ~$895 per token and now holds about 18,840 BNB via direct holdings and OBNB trust units. Following a restructuring, LineaRx reduced costs and increased shipments and is expected to significantly narrow losses and approach profitability in FY26Q1 (ending Dec 31, 2025).
Applied DNA announced it will rebrand as BNB Plus Corp. (ticker BNBX) on November 17, 2025 to emphasize a yield‑optimized, BNB‑based digital asset treasury strategy leveraging the Binance ecosystem.
The company appointed Josh Kruger as Chairman of the Board; Kruger is founder of OnChain Alpha and previously served as Head of Trading at Coral Capital, which was acquired by DNA Fund in late 2024. Judy Murrah voluntarily stepped down as Chairperson and will remain a director. The firm said it has initiated a formal rebranding, including a soon‑to‑launch website at BNB.plus, and will share further updates as the transition progresses.
Applied DNA Sciences (NASDAQ: BNBX) launched BNBX.io, a real-time dashboard showing the company’s BNB treasury holdings, valuation metrics, and capitalization details.
Corporate update as of Oct 27, 2025: 4.35M shares outstanding, 23.71M fully diluted shares, ~15,553 BNB held via direct holdings and OBNB Trust units, and $8.4M cash. The company recently closed a private placement of up to $58M to support a yield-focused BNB treasury strategy and plans a weekly BNB newsletter plus additional dashboard features.
Applied DNA Sciences (NASDAQ: BNBX) closed a private placement (PIPE) on October 22, 2025, generating approximately $27.0 million gross proceeds with the potential for up to an additional $31 million from future warrant exercises. Gross proceeds included $15.3 million in cash and stablecoins and $11.71 million in OBNB trust units.
The company received 435,638 trust units representing underlying ownership of 10,647 BNB tokens and separately purchased an additional 4,908 BNB tokens (~$5.3M as of Oct 20, 2025). Prefunded warrants and related warrants are not exercisable until stockholder approval. Applied DNA also reported streamlining actions yielding approximately $2.9M in annualized cost savings and intends to use proceeds to implement its BNB treasury strategy and support working capital.
FAQ
What is the current stock price of BNB Plus (BNBX)?
What is the market cap of BNB Plus (BNBX)?
